PP405
MPC Inhibitor | Hair Follicle Stem Cell Activation
Community Research
Join others researching PP405 — share findings, ask questions, and learn from real experiences
PP405 is an investigational topical drug developed by Pelage Pharmaceuticals for the treatment of androgenetic alopecia. Based on research conducted at UCLA, PP405 works through a fundamentally different mechanism than existing hair loss treatments: rather than blocking androgens like finasteride or promoting blood flow like minoxidil, it targets the metabolic dormancy of hair follicle stem cells directly. By inhibiting the mitochondrial pyruvate carrier (MPC1/MPC2), PP405 causes pyruvate accumulation in hair follicle stem cells, stimulating lactate dehydrogenase activity and triggering a metabolic shift that reactivates dormant follicles. Phase 2a clinical trial results showed increased hair count and thickness with a 0.05% gel formulation applied once daily. As of 2025, the drug has completed Phase 2a trials, with Phase 3 trials planned for 2026.
PP405 is a dual inhibitor of the mitochondrial pyruvate carrier complex, targeting both the MPC1 and MPC2 subunits. Under normal conditions, the MPC transports pyruvate from the cytoplasm into the mitochondrial matrix, where it enters the tricarboxylic acid (TCA) cycle for oxidative metabolism. In hair follicle stem cells (HFSCs), this standard metabolic pathway is associated with quiescence and dormancy. By blocking MPC1/MPC2, PP405 prevents pyruvate from entering the mitochondria, causing it to accumulate in the cytoplasm. This pyruvate buildup stimulates lactate dehydrogenase (LDH) activity, which converts pyruvate to lactate, shifting the cell's metabolic profile toward aerobic glycolysis. This metabolic reprogramming mimics the signaling environment that naturally triggers HFSCs to exit quiescence and re-enter the cell cycle. The activated stem cells then initiate a new anagen (growth) phase in dormant hair follicles. Critically, this mechanism is entirely independent of the androgen/DHT pathway targeted by finasteride and dutasteride, and distinct from the vasodilatory effects of minoxidil, meaning PP405 could be effective regardless of a patient's androgen status.
Molecular Data
Research Indications
Currently in Phase 2 clinical trials for the treatment of androgenetic alopecia. Phase 2a results showed measurable increases in hair count and thickness with the 0.05% topical gel formulation.
PP405 directly targets metabolic dormancy in hair follicle stem cells by inhibiting MPC1/MPC2 and promoting anagen re-entry. This mechanism may address follicle miniaturization at an earlier stage than androgen-blocking approaches.
Dosing Protocols
PP405 is formulated as a 0.05% topical gel for once-daily application to the scalp. This is the only formulation currently under clinical investigation. The topical route delivers the active compound directly to the hair follicle environment while minimizing systemic absorption. Application involves a thin layer of gel spread across affected areas of the scalp.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Androgenetic alopecia treatment (Phase 2 trial protocol) | 0.05% gel | Once daily | Topical application to scalp |
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Scalp irritation at the application site
- Application site reactions (redness, dryness, itching)
Stop Signs - Discontinue if:
- Severe or persistent scalp irritation that does not resolve
- Signs of allergic reaction (significant swelling, rash spreading beyond the application site)
- Any unexpected systemic symptoms following application
Contraindications
- Known hypersensitivity to PP405 or any component of the gel formulation
- Full contraindication profile has not been established (investigational drug)
- Pregnant or breastfeeding women should avoid use until safety data is available
Quality Checklist
Good Signs
- Obtained through an authorized clinical trial site or Pelage Pharmaceuticals directly
- Properly labeled with lot number, expiration date, and clinical trial identifiers
- Stored per protocol instructions provided by the trial site
- Prescribed or dispensed by a licensed investigator as part of an approved clinical trial
Warning Signs
- Products marketed as 'PP405' or 'JXL-069' from research chemical vendors are NOT verified by Pelage Pharmaceuticals
- Any product claiming to be PP405 that is not sourced from an active clinical trial
- Grey market formulations with unverified concentrations or purity
Bad Signs
- Research chemical vendor products sold as PP405 or JXL-069 without regulatory oversight
- Products without certificate of analysis, batch numbers, or manufacturer information
- Any PP405 product purchased outside of a regulated clinical trial or pharmacy setting
- Formulations with undisclosed ingredients or unverifiable provenance
References
- Safety, Pharmacokinetics and Efficacy of PP405 in Adults With Androgenetic AlopeciaPelage PharmaceuticalsClinicalTrials.gov (2024)
Phase 2a clinical trial evaluating the safety, pharmacokinetics, and efficacy of PP405 topical gel in adults with androgenetic alopecia. The study assessed the 0.05% gel formulation applied once daily, with endpoints including hair count, hair thickness, and safety measures.
- Lactate and pyruvate promote oxidative stress resistance through hormetic ROS signalingLowry WE et al.UCLA / Cell Metabolism (associated research) (2019)
UCLA research demonstrating that manipulation of the lactate/pyruvate metabolic axis in hair follicle stem cells can drive these cells out of quiescence. Inhibiting mitochondrial pyruvate carriers causes cytoplasmic pyruvate accumulation, activates lactate dehydrogenase, and promotes a glycolytic shift that triggers hair follicle stem cell activation and anagen entry. This foundational research underpins the mechanism of action of PP405.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.